Mark Talamonti to Neuroendocrine Tumors
This is a "connection" page, showing publications Mark Talamonti has written about Neuroendocrine Tumors.
Connection Strength
1.484
-
Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013 Oct; 154(4):785-91; discussion 791-3.
Score: 0.412
-
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007 Oct; 205(4):558-63.
Score: 0.268
-
Number of Hepatic Resections and Association with Complication after Metastatic Neuroendocrine Tumor Debulking: An American College of Surgeons NSQIP Database Study. J Am Coll Surg. 2023 07 01; 237(1):157-168.
Score: 0.199
-
Clinical features of primary and metastatic hepatic malignancies. Cancer Treat Res. 2001; 109:1-14.
Score: 0.170
-
Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
Score: 0.111
-
Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015 Jan; 19(1):117-23; discussion 123.
Score: 0.110
-
Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg. 2009 Sep; 13(9):1692-8.
Score: 0.077
-
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008 Mar; 247(3):490-500.
Score: 0.070
-
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007 Nov; 11(11):1460-7; discussion 1467-9.
Score: 0.068